A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer

This study is testing whether combining androgen deprivation therapy (hormone-blocking treatment) with anti-PD-1 immunotherapy can improve outcomes for men with advanced lung cancer. The idea is that lowering testosterone levels may make cancer cells more vulnerable to immune attack. **You may be eligible if...** - You are a male patient aged 60 or older - You have been confirmed by biopsy to have advanced lung cancer - You have not previously received any anti-PD-1 immunotherapy - Your expected survival is more than 3 months - Your physical performance is good (ECOG 0-1) - You have adequate bone marrow and organ function - You have at least one measurable tumor lesion **You may NOT be eligible if...** - You are female (this study only enrolls males) - You have previously received anti-PD-1 immunotherapy - You are under 60 years old - Your expected survival is less than 3 months - You have serious organ dysfunction Talk to your doctor to see if this trial is right for you.